Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:9/12/2007

SOMERSET, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced it has confirmed that 290 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. The number of evaluable events was confirmed after the company learned that total events in the study had reached 316. In accordance with the statistical plan for the study, the company must wait until 316 evaluable events have occurred to conduct the formal statistical analysis required to complete the ONCONASE New Drug Application (NDA). Enrollment in the ONCONASE Phase IIIb clinical trial is scheduled to close on Sept. 30, 2007. To date, a total of 425 patients have been enrolled in the trial.

To be considered evaluable, patients must meet all of the eligibility requirements for the study and receive at least one dose of study drug. Alfacell projects that 316 evaluable events will occur before the end of 2007. Upon reaching this milestone, the company expects to proceed using the following schedule to provide updates regarding the potential completion of the final sections of its ONCONASE rolling NDA submission:

-- Report occurrence of 316 evaluable events via news release within 72

hours of confirmation by Alfacell

-- If data are positive, submit final clinical section of rolling NDA

within four months of reporting 316 evaluable events and announce

submission via news release

Alfacell estimates that it has sufficient cash resources available to continue to fund the completion of the ONCONASE Phase III program and the rolling NDA submission.

In additi
'/>"/>

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
10. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
11. NCCN Updates Esophageal and Gastric Cancer Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...karia Holdings, Inc. today announced that it has b...ersey Technology Council (NJTC), a 1,200-member no...rt, networking opportunities, information and advo...karia earned the award based on criteria including...ision. , , "We are delighted that the New J...
(Date:11/20/2008)...T PHASE III TRIAL SHOW SIGNIFICANT, DECREASES...CTION, IN, FIBROMYALGI... Belgium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz ...uronext Brussels: UCB),announced today positive p...,Phase III pivotal clinical trials of sodium oxyba...
(Date:11/20/2008)...- Radius Health ("Radius") announced today that it...d institutional financing round, increasing total ... amount raised since the company,s inception to $1... participated in the financing, led by MPM Bio IV ...Wellcome Trust, HealthCare Ventures, Oxford Biosci...
(Date:11/19/2008)...re-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and Mill...of,Takeda Pharmaceutical Company Limited (TSE: 40... 3 MONET1 trial evaluating motesanib (AMG 706) in,...he first-line treatment of,advanced non-small cel...ed,following a planned safety data review of 600 ...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 1Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 2Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 3Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 4Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 5Coastal management cooperation enforcement key to avoid pending crisis for millions 3A U N experts 3532 6Regular tipple may curb risk of rheumatoid arthritis 21104 1Regular tipple may curb risk of rheumatoid arthritis 21104 2Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 1Trust for Americas Health on New HHS Influenza Pandemic Draft Guidance 21100 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 1MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 2MultiVu Video Feed 3A Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna 28R 29 Reduces Key Marker of Kidney Disease 21096 3
(Date:11/21/2008)...ov. 21, 2008)The University of Texas Health Scienc...ining Excellence in Aging Studies (TEXAS), to prom...restigious $2 million award from the Donald W. Rey...ds., "This will allow us to teach geriatric medic...dical student to practicing physicians. With the r...
(Date:11/21/2008)...Colo., Nov. 21 Heska Cor...l present at the New York Society of,Security Ana...nference on,December 2, 2008 at 1177 Avenue of th...tation is scheduled to begin at 9:35 a.m. Eastern ...ble via live webcast and for two weeks,following ...
(Date:11/21/2008)... Va., Nov. 21 The Gener... following statement today from,GPhA President an...Commission,(FTC) roundtable on "Emerging Health C...e mere fact that the FTC is conducting this roundt...uring that consumers have access to safe and,affo...
(Date:11/21/2008)...wed Banzel proved effective against Lennox-Gastaut... News) -- A new drug called Banzel (rufinamide) ha... severe form of epilepsy called Lennox-Gastaut syn...nced Friday. , The approval was based on result...ients ages 4 to 30. Compared to patients who took ...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:FDA Approves New Drug for Severe Epilepsy 2
...umpy old man’, ‘old fogies’ and other such, this i...ersity//. Surprisingly, it’s older people who are ... that people become more positive as they get olde...d to have a "glass empty" view of the world. As ...
...that can keep arteries healthy and prevent heart a...ast one orange// a day could keep cardiac disease ...anones that reduced blood cholesterol levels by 20...on rats, reported the online edition of Daily Mail...
... stress better than those live single, says a stud...r//. Popular perception is that single people have...ws that being in a loving relationship makes it ea...ains of working life, reported online edition of D...
... at Weill Cornell Medical College could prove a po...The compound, called SS31, is able to cross the bl...molecule recently linked to stroke-related tissue ...s, we found that exposing mice to SS31 after an in...
Other Medicine News:Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: